In a prospective and randomized study, Navarro et al. showed an additional effect on the reduction of urinary albumin excretion of treatment with pentoxifylline in a group of patients with type 2 diabetes and diabetic nephropathy and residual albuminuria despite long-term therapy with angiotensin II receptor blockers at the recommended dosage [27]. Here, ALB is linked to diabetic kidney disease.